Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R K Hills

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Leukemia|November 8, 2014
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemiaN H Russell, L Kjeldsen, C Craddock, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 7, 2013
PROSPER: a randomised comparison of surgical treatments for rectal prolapseA Senapati, R G Gray, L J Middleton, et al.
Leukemia|November 24, 2005
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trialsB E S Gibson, K Wheatley, I M Hann, et al.
Leukemia|April 9, 2011
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcomeA K Burnett, R K Hills, A Hunter, et al.
Leukemia|June 21, 2013
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemiaC Allen, R K Hills, K Lamb, et al.
Leukemia|September 12, 2012
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparisonA K Burnett, R K Hills, A E Hunter, et al.
Leukemia|November 1, 2016
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemiaN Khan, R K Hills, P Virgo, et al.
Leukemia|September 15, 2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemiaA K Burnett, N H Russell, R K Hills, et al.
Leukemia|December 11, 2012
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trialA K Burnett, R K Hills, D Grimwade, et al.
Human Reproduction Update|July 17, 2010
Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic painJ P Daniels, L Middleton, T Xiong, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Leukemia|November 8, 2014
A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemiaN H Russell, L Kjeldsen, C Craddock, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|March 7, 2013
PROSPER: a randomised comparison of surgical treatments for rectal prolapseA Senapati, R G Gray, L J Middleton, et al.
Leukemia|November 24, 2005
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trialsB E S Gibson, K Wheatley, I M Hann, et al.
Leukemia|April 9, 2011
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcomeA K Burnett, R K Hills, A Hunter, et al.
Leukemia|June 21, 2013
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemiaC Allen, R K Hills, K Lamb, et al.
Leukemia|September 12, 2012
The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparisonA K Burnett, R K Hills, A E Hunter, et al.
Leukemia|November 1, 2016
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemiaN Khan, R K Hills, P Virgo, et al.
Leukemia|September 15, 2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemiaA K Burnett, N H Russell, R K Hills, et al.
Leukemia|December 11, 2012
Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trialA K Burnett, R K Hills, D Grimwade, et al.
Human Reproduction Update|July 17, 2010
Individual patient data meta-analysis of randomized evidence to assess the effectiveness of laparoscopic uterosacral nerve ablation in chronic pelvic painJ P Daniels, L Middleton, T Xiong, et al.
Pageof 3